Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe
Creators: name: Zhang, Jingchuan
name: Kelkar, Sneha S
name: Prabhu, Vimalanand S
name: Ogando, Yoscar M
name: Verma, Rishi P
name: Grall, Véronique
name: Marth, Christian
Publisher: name: Taylor & Francis
Year: 2024
Subjects: Medicine
Pharmacology
Biotechnology
Environmental Sciences not elsewhere classified
Biological Sciences not elsewhere classified
Mathematical Sciences not elsewhere classified
Cancer
Science Policy

description: <b>Background:</b> The treatment patterns and clinical outcomes in recurrent/advanced endometrial cancer in Europe are not well known. <b>Materials &amp; methods:</b> Endometrial Cancer Health Outcomes-Europe-First-Line is a multicenter, retrospective chart review study conducted in the UK, Germany, Italy, France and Spain. Patients diagnosed with recurrent/advanced endometrial cancer who initiated first-line systemic therapy between 1 July 2016 and 31 March 2020 were eligible. <b>Results:</b> Among 242 patients, median age was 69 years and 82.2% had stage IIIB-IV disease. In first-line, most patients received platinum-based chemotherapy (78.9%); others received endocrine therapy (6.2%), taxane monotherapy (5.8%) and nonplatinum or taxane-based chemotherapy (4.1%). Median real-world progression-free survival since first-line initiation was 10.8 months and median overall survival was 20.7 months. <b>Conclusion:</b> Poor prognosis with platinum-based first-line chemotherapy suggests significant unmet medical need. <b>Treatment patterns &amp; survival for recurrent/advanced endometrial cancer patients in Europe who received their first treatment</b> The treatments and survival for recurrent/advanced endometrial (uterus lining) cancer patients in real-life European settings are not well known. Endometrial Cancer Health Outcomes-Europe-First-Line is a multicenter study that was conducted in the UK, Germany, Italy, France and Spain and used de-identified information from existing patient medical records. Patients diagnosed with recurrent/advanced endometrial cancer who initiated a first treatment between 1 July 2016 and 31 March 2020 were included. Among 242 included patients, the average age was 69 years and 82.2% had stage IIIB-IV disease (indicating the size and extent of their cancer). As their first treatment, most patients received platinum-based chemotherapy (78.9%), which is a type of drug that kills cancer cells. Overall, patients lived for an average of 20.7 months since their first treatment. The average length of time patients lived without their disease getting worse was 10.8 months since their first treatment. We found that patients who received platinum-based chemotherapy as their first treatment had poor survival, which suggests significant unmet medical need. First multicountry, real-world study in recurrent/advanced endometrial cancer patients in first-line settings in Europe. Most patients in our study initiated first-line therapy with chemotherapy or endocrine therapy. Our study found poor clinical outcomes and considerable healthcare resource burden in patients overall. Findings indicate unmet medical need among recurrent/advanced endometrial cancer patients in European first-line settings. Novel therapies with potential to improve survival outcomes and provide clinical benefit are needed for these patients.